Format

Send to

Choose Destination
Aliment Pharmacol Ther. 2017 Mar;45(5):681-687. doi: 10.1111/apt.13923. Epub 2017 Jan 9.

Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.

Author information

1
Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
2
Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt.
3
Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansora, Egypt.
4
Internal Medicine Department, Faculty of Medicine, Menia University, Minia, Egypt.
5
Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
6
Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
7
Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
8
Department of Hepatology, National Liver Institute, Menoufyia University, Menoufyia, Egypt.
9
Department of Hepatology, Imperial College London, London, UK.

Abstract

BACKGROUND:

Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment Programme introduced sofosbuvir-based therapy in October 2014.

AIM:

To assess the clinical effectiveness and predictors of response to SOF-based treatment regimens, either dual therapy, with SOF/ribavirin (RBV) for 6 months or triple therapy with SOF/peg-IFN-alfa-2a/RBV for 3 months, in a cohort of patients treated in National Treatment Programme affiliated centres in Egypt.

METHODS:

Between October 2014 and end of 2014, patients who were eligible for treatment were classified according to their eligibility for interferon therapy: Group 1 (interferon eligible) were treated with triple therapy for 12 weeks and Group 2 (interferon ineligible) were treated with dual therapy for 24 weeks. Difficult to treat patients included those with F3-F4 on Metavir score, Fib-4 >3.25, albumin ≤3.5, total Bilirubin >1.2 mg/dL, INR >1.2 and platelet count <150 000 mm3 .

RESULTS:

Twelve weeks post-treatment data were available on 14 409 patients; 8742 in group 1 and 5667 in group 2. In group 1, the sustained virological response at week 12 (SVR12) was 94% and in group 2 the SVR12 was 78.7%. Multivariate logistic regression analysis in which treatment failure is the dependent variable was done. Male gender, being a difficult to treat patient and previous interferon therapy were significant predictors of nonresponse in both treatment groups.

CONCLUSION:

Results of sofosbuvir-based therapies in Egypt achieved similar rates of SVR12 as seen in phase III efficacy studies.

PMID:
28070899
DOI:
10.1111/apt.13923
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center